(Q42661055)

4 November 2017

Rising multiple-dose pharmacokinetics of labetalol in hypertensive patients (English)

1 reference

4 November 2017

1 reference

Chung M

1

1 reference

4 November 2017

Leitz FH

2

1 reference

4 November 2017

Maier G

3

1 reference

4 November 2017

Patrick JE

4

1 reference

4 November 2017

Gural RP

5

1 reference

4 November 2017

Symchowicz S

6

1 reference

4 November 2017

1 April 1986

1 reference

The Journal of Clinical Pharmacology

4 November 2017

1 reference

4 November 2017

26

1 reference

4 November 2017

4

1 reference

4 November 2017

248-252

1 reference

Labetalol: a review of its pharmacology and therapeutic use in hypertension

4 November 2017

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB03518.X

Labetalol: A Review of Its Pharmacology, Pharmacokinetics, Clinical Uses and Adverse Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB03518.X

Study of single and multiple dose pharmacokinetic/pharmacodynamic modeling of the antihypertensive effects of labetalol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB03518.X

Computation of model-independent pharmacokinetic parameters during multiple dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB03518.X

The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB03518.X

10.1002/J.1552-4604.1986.TB03518.X

21 January 2018

Identifiers

DOI

1 reference

4 November 2017

1 reference